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Plasmodium falciparum
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Abstract
Background: The aim of the present work was to assess i) ex vivo activity of pyronaridine (PND) and piperaquine (PPQ),
as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities
compared to other partner drugs, namely monodesethylamodiaquine (MDAQ), lumefantrine (LMF), mefloquine (MQ),
artesunate (AS) and dihydroartemisinin (DHA) against 181 Plasmodium falciparum isolates from African countries, India
and Thailand, and iii) in vitro cross-resistance with other quinoline drugs, chloroquine (CQ) or quinine (QN).
Methods: The susceptibility of the 181 P. falciparum isolates to the nine anti-malarial drugs was assessed using the
standard 42-hours 3H-hypoxanthine uptake inhibition method.
Results: The IC50 values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM) and from 11.8 to 217.3
nM for PPQ (geometric mean = 66.8 nM). A significant positive correlation was shown between responses to PPQ
and PND responses (rho = 0.46) and between PPQ and MDAQ (rho = 0.30). No significant correlation was shown
between PPQ IC50 and responses to other anti-malarial drugs. A significant positive correlation was shown between
responses to PND and MDAQ (rho = 0.37), PND and LMF (rho = 0.28), PND and QN (rho = 0.24), PND and AS (rho
= 0.19), PND and DHA (rho = 0.18) and PND and CQ (rho = 0.16). All these coefficients of correlation are too low
to suggest cross-resistance between PPQ or PND and the other drugs.
Conclusions: In this study, the excellent anti-malarial activity of PPQ and PND was confirmed. The absence of
cross-resistance with quinolines and artemisinin derivatives is consistent with the efficacy of the combinations of
PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs.
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Background
During the past 20 years, many strains of Plasmodium
falciparum have become resistant to chloroquine and
other anti-malarial drugs [1]. This has prompted a
search for an effective alternative anti-malarial drug
with minimal side effects. The emergence and spread of
parasites resistant to anti-malarial drugs has caused an
urgent need for novel compounds to be discovered and
developed. One strategy for reducing the prevalence of
malaria is the combinatorial use of drugs. The combina-
tion protects each drug from the development of resis-
tance and reduces the overall transmission of malaria
[2]. The official first-line anti-malarial policy is now
artemisinin-based combination therapy (ACT) [3]. The
artemisinin derivative causes rapid and effective reduc-
tion of the parasite biomass and gametocytes carriage,
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while the partner drug, which has a longer duration of
action, achieves effective clinical and parasitological
cure. Different formulations of ACT were evaluated:
artesunate-sulphadoxine-pyrimethamine [4], artesunate-
amodiaquine [5], artemether-lumefantrine [6], artesu-
nate-mefloquine [7], artesunate-chlorproguanil-dapsone
[8], dihydroartemisinin-piperaquine [9] and artesunate-
pyronaridine [10].
However, suspected decreased susceptibility of ACT
or, at least, longer parasite clearance times have been
described in Cambodia [11-14]. In addition, prior ther-
apy by amodiaquine-containing ACT selected reduced
response to monodesethylamodiaquine, suggested that
amodiaquine-containing regimens may rapidly lose effi-
cacy in Africa [15]. This emergence of parasite resis-
tance to ACT indicates that novel compounds and
combinations need to be discovered and developed.
The aim of the present work was to assess i) ex vivo
activity of two recent ACT partner drugs, pyronaridine
(PND) and piperaquine (PPQ) to define the susceptibil-
ity baseline, ii) comparison with standard components
of ACT, such as monodesethylamodiaquine (the active
metabolite of amodiaquine) (MDAQ), lumefantrine
(LMF), mefloquine (MQ), artesunate (AS) or dihydroar-
temisinin (DHA), and iii) in vitro cross-resistance with
other quinoline drugs, such as chloroquine (CQ) and
quinine (QN).
Methods
Plasmodium falciparum isolates
In total, 181 P. falciparum isolates were collected
between April 2008 and April 2010 from patients hospi-
talized in France with imported malaria from a malaria-
endemic country (Angola, Benin, Burkina Faso, Camer-
oon, Comoros, Congo, Ivory Coast, Gabon, Gambia,
Ghana, Guinea, India, Madagascar, Mali, Mozambique,
Niger, Central African Republic, Senegal, Thailand,
Togo, Zambia). Informed consent was not required for
this study as the sampling procedures and testing are
part of the French national recommendations for the
care and surveillance of malaria. Venous blood samples
were collected in Vacutainer® ACD tubes (Becton Dick-
inson, Rutherford, NJ, USA) before treatment and trans-
ported at 4°C from French hospitals located in
Marseille, Toulouse, Bordeaux, Lyon, Montpellier, Nice,
Toulon, Nimes or Grenoble, to the Institute of Biomedi-
cal Research of the French Army (IRBA) in Marseille
within less than 72 hours of collection. The Case Report
Form was provided at the same time as a paper copy or
electronically.
Thin blood smears were stained using a RAL® kit
(Réactifs RAL, Paris, France) and examined to determine
the P. falciparum density and to confirm monoinfection.
Parasitized erythrocytes were washed three times in
RPMI 1640 medium (Invitrogen, Paisley, UK), buffered
with 25 mM HEPES and 25 mM NaHCO3. If parasitae-
mia exceeded 0.8%, infected
erythrocytes were diluted to 0.5-0.8% with uninfected
erythrocytes (human blood type A+) and re-suspended
in RPMI 1640 medium supplemented with 10% human
serum (Abcys S.A. Paris, France) to a haematocrit of
1.5%.
Drugs
PPQ, PND, DHA and AS were obtained from Shin
Poong Pharm Co. (Seoul, Korea). CQ and QN were pur-
chased from Sigma (Saint Louis, MO). MDAQ was
obtained from the World Health Organization (Geneva,
Switzerland), MQ from Roche (Paris, France) and LMF
from Novartis Pharma (Basel, Switzerland). PPQ, QN,
MDAQ, MQ, DHA and AS were dissolved first in
methanol and then diluted in water to obtain final con-
centration ranging from 0.8 to 1,000 nM for PPQ, 5 to
3,200 nM for QN, 1.56 to 1,000 nM for MDAQ, 3.2 to
400 nM for MQ and 0.1 to 100 nM for DHA and AS.
PND and CQ were dissolved and diluted in water in
concentrations ranging between 0.15 to 100 nM for
PND, 5 to 3,200 nM for CQ. LMF was dissolved and
diluted in ethanol to obtain final concentration ranging
from 0.5 to 310 nM.
Ex vivo assay
The new term ‘ex vivo susceptibility’ is used to
describe studies on fresh isolates, while the term of ‘in
vitro susceptibility’ should now refer to studies on
strains of parasites, which have been either kept in cul-
ture for at least two to three generations or which have
been cryo-preserved. For ex vivo isotopic microtests,
200 μl/well of the suspension of synchronous parasi-
tized red blood cells (final parasitaemia, 0.5%; final
haematocrit, 1.5%) were distributed in 96-well plates
pre-dosed with anti-malarial drugs. Parasite growth
was assessed by adding 1 μCi of tritiated hypoxanthine
with a specific activity of 14.1 Ci/mmol (Perkin-Elmer,
Courtaboeuf, France) to each well at time zero. The
plates were then incubated for 42 hours in controlled
atmospheric conditions that consisted of 10% O2, 5%
CO2, and 85% N2 at 37°C with a humidity of 95%.
Immediately after incubation, plates were frozen and
then thawed to lyse erythrocytes. The content of each
well was collected on standard filter microplates (Uni-
filter GF/B; Perkin-Elmer) and washed using a cell har-
vester (Filter-Mate Cell Harvester; Perkin-Elmer). Filter
microplates were dried, and 25 μl of scintillation cock-
tail (Microscint O; Perkin-Elmer) was placed in each
well. Radioactivity incorporated in nucleotides by the
parasites was measured with a scintillation counter
(Top Count; Perkin-Elmer).
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Internal controls were used (testing of 3D7 and W2 P.
falciparum clones maintained in continuous culture) in
order to validate the results. All strains were synchro-
nized twice with sorbitol before use [16].
Clonality was verified using PCR genotyping of poly-
morphic genetic markers msp1, msp2, and microsatellite
loci [17,18].
The drug concentration that inhibits 50% of parasite
growth (IC50) was defined as the drug concentration
corresponding to 50% of the incorporation of tritiated
hypoxanthine by the parasite in the drug-free control
wells. The IC50 value was determined by non-linear
regression analysis of log-based dose-response curves
(Riasmart™, Packard, Meriden, USA).
Statistical analysis
Data of ex vivo susceptibility of P. falciparum parasites
were analysed after logarithmic transformation and
expressed as the geometric mean of the IC50 and the
95% confidence interval (95% CI). Cross-resistance
between the nine drugs was assessed by a pair-wise cor-
relation of IC50 values of all isolates and estimated by
coefficient of correlation of Spearman (rho) (non-para-
metric test), coefficient of correlation of Pearson (r)
(parametric test) and coefficient of determination (r2).
Results
One hundred and eighty one P. falciparum isolates were
tested for their ex vivo susceptibility to PPQ, PND, CQ,
QN, MQ, MDAQ, LMF, DHA and AS. The mean IC50s
for these nine anti-malarial drugs are presented in Table
1. The IC50 values for PND ranged from 0.55 to 80.0
nM (geometric mean = 19.9 nM, 95% = CI 18.0-022.0)
and from 11.8 to 217.3 nM for PPQ (geometric mean =
66.8 nM, 95% CI = 61.8-72.3). The distributions of the
IC50 for the nine anti-malarial drugs are presented in
Figure 1.
In vitro cross-resistance was measured by pair-wise
correlation of IC50 values of 181 isolates (Table 2). A
significant positive correlation was shown between
responses to PPQ and PND responses (rho = 0.46; P <
0.00001) and between PPQ and MDAQ (rho = 0.30; P =
0.0001). No significant correlation was shown between
PPQ IC50 and responses to other anti-malarial drugs. A
significant positive correlation was shown between
responses to PND and MDAQ (rho = 0.37; P <
0.00001), LMF (rho = 0.28; P = 0.0002), QN (rho = 0.24;
P = 0.0012), AS (rho = 0.19; P = 0.0108), DHA (rho =
0.18; P = 0.0173) and CQ (rho = 0.16; P = 0.0365). The
highest coefficients of correlation were shown for corre-
lation between responses to DHA and AS (rho = 0.84; P
< 0.00001), LMF and MQ (rho = 0.58; P < 0.00001), CQ
and MDAQ (rho = 0.51; P < 0.00001), LMF and DHA
(rho = 0.46; P < 0.00001), LMF and AS (rho = 0.45; P <
0.00001) or CQ and QN (rho = 0.41; P < 0.00001).
Isolates with high IC50 to at least one of the anti-
malarial drug are listed in Table 3. One originated from
Thailand with IC50 = 71.5 nM for PND associated with
IC50 = 91.1 nM for PPQ, IC50 = 1,131 nM for QN,
IC50 = 166 nM for MQ, IC50 = 114 nM for LMF, IC50
= 21.2 nM for DHA and IC50 = 16.3 nM for AS.
Discussion
Ex vivo analysis of the susceptibility of P. falciparum
isolates to anti-malarial drugs has three important attri-
butes. This approach allows firstly to assay the response
of clinical isolates to individual drugs that are unmodi-
fied by important host factors that influence drug effi-
cacy in vivo. Secondly, the progressive decline in drug
susceptibility of isolates from the same site may identify
incipient resistance in the parasite population. Finally,
strains with reduced anti-malarial susceptibilities can
then be established in continuous culture to provide the
material needed to investigate novel molecular
Table 1 Ex vivo susceptibility of the 181 isolates of Plasmodium falciparum to pyronaridine (PND), piperaquine (PPQ),
chloroquine (CQ), quinine (QN), mefloquine (MQ), monodesethylamodiaquine (MDAQ), lumefantrine (LMF),
dihydroartemisinin (DHA) and artesunate (AS)
IC50 in nM
Drugs No geometric mean 95% Confidence Interval min Q25 median Q75 max
PND 176 19.9 18.0-22.0 0.55 15.0 19.4 32.1 80.0
PPQ 179 66.8 61.8-72.3 11.8 48.0 76.7 90.5 217.3
CQ 181 79.8 66.6-95.6 5.0 22.9 96.0 246.0 1918.0
QN 181 254.6 234.7-276.1 54.8 182.0 265.0 358.0 1131.0
MQ 181 15.5 13.6-17.6 3.0 8.9 15.8 29.7 166.0
MDAQ 181 22.1 19.1-25.6 1.5 11.8 22.6 43.3 240.0
LMF 181 7.3 6.1-8.8 0.25 5.5 8.0 17.7 114.0
DHA 181 1.3 1.2-1.5 0.10 0.9 1.4 2.4 21.2
AS 179 1.1 1.0-1.3 0.10 0.7 1.3 2.1 20.6
Min: IC50 minimum Max: IC50 maximun
Q25: 1st quartile Q75: 3rd quartile
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mechanisms of resistance as well as for tests of suscept-
ibility to other anti-malarial agents.
The continued spread of P. falciparum drug resistance
to monotherapies has forced a shift toward the use of
ACT. Nevertheless, resistance to at least one component
of many of the different formulations of ACT currently
in clinical use has been documented, and it is feared
that the widespread use of ACT will gradually reduce its
clinical efficacy. Clinical failures or at least longer para-
site clearance times have been described in Cambodia
[12]. In addition, prior therapy by amodiaquine-contain-
ing ACT selected reduced response to monodesethyla-
modiaquine, suggested that amodiaquine-containing
regimens may rapidly lose efficacy in Africa [15].
One hundred and eighty one P. falciparum strains
were tested for their in vitro susceptibility to PPQ, PND,
CQ, QN, MQ, MDAQ, LMF, DHA and AS. The IC50
values for PND ranged from 0.55 to 80.0 nM (geometric
mean = 19.9 nM, 95% CI = 18.0-22.0). These values are
in accordance with previous studies on P. falciparum
strains (1.9-47.8 nM and 15-49 nM, respectively) [19,20]
or in isolates from patients in Thailand cured with PND
(geometric mean = 15.7 nM) or that recrudesced after
PND treatment (geometric mean = 23.0 nM) [21] but
higher than those found in isolates from Cameroon
(geometric mean = 3.58 nM), Senegal (geometric mean
= 3.8 nM and 4.52 nM), Gabon (geometric mean = 3.0
nM and 1.87 nM) [22-26] and in Indonesia (geometric
mean = 1.92 nM) [27]. In addition, PND is also effective
in vitro against Plasmodium vivax isolates (geometric
mean = 2.58 nM) [27].
Antagonistic in vitro drug interactions between PND
and artemisinin derivatives have been described
[22,28,29]. Previous studies have demonstrated in vitro
cross-resistance between PND and DHA or CQ, with
coefficients of determination (r2) of 0.84 and 0.19-0.46,
respectively [19,21,23-25]. A low r2 (0.20) was deter-
mined between PND and AS in P. falciparum strains
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Figure 1 Dot plots of IC50 values in nM for chloroquine (CQ), quinine (QN), pyronaridine (PND), piperaquine (PPQ), mefloquine (MQ),
monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA) and artesunate (AS). Each dot represents one
isolate.
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Table 2 Spearman correlation (rho) and Pearson correlation (r2) of in vitro responses of 181 isolates of Plasmodium
falciparum to pyronaridine (PND), piperaquine (PPQ), chloroquine (CQ), quinine (QN), mefloquine (MQ),
monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA) and artesunate (AS)
CQ QN MQ DHA AS MDAQ LMF PND
QN Rho 0,4143
p-value < 0,00001
r2 0.159
MQ Rho -0,1254 0,1139
p-value 0,0936 0,128
r2 0.020 0.008
DHA Rho -0,1471 0,134 0,3164
p-value 0,0488 0,0729 < 0,00001
r2 0.026 0.020 0.109
AS Rho -0,1196 0,1291 0,364 0,8374
p-value 0,1109 0,0851 < 0,00001 < 0,00001
r2 0.013 0.013 0.124 0.681
MDAQ Rho 0,5071 0,0997 -0,115 -0,1615 -0,0769
p-value < 0,00001 0,1831 0,1243 0,0303 0,3074
r2 0.227 0.012 0.014 0.028 0.005
LMF Rho -0,1799 0,126 0,5821 0,4636 0,4533 -0,1451
p-value 0,0156 0,0918 < 0,00001 < 0,00001 < 0,00001 0,0519
r2 0.030 0.014 0.300 0.189 0.163 0.012
PND Rho 0,1582 0,2425 0,0711 0,1798 0,1933 0,3658 0,2776
p-value 0,0365 0,0012 0,3496 0,0173 0,0108 < 0,00001 0,0002
r2 0.017 0.060 0.003 0.027 0.038 0.101 0.082
PPQ Rho 0,036 0,0478 -0,0203 -0,0766 -0,06 0,2988 0,1234 0,4672
p-value 0,6336 0,5263 0,7881 0,3094 0,4288 0,0001 0,1007 < 0,00001
r2 < 0.001 0.002 < 0.001 0.001 0.001 0.096 0.029 0.230
Table 3 Isolates with high IC50 to at least one anti-malarial drug among the 181 isolates tested
Isolates IC50 in nM
origin PND PPQ CQ QN MQ MDAQ LMF DHA AS
Mali ND 175 22 185 23.4 44.8 25.8 1.2 2.0
Comoros ND 177.5 130 460 27.6 76.4 15.8 1.2 3.2
Cameroon 15.0 189 171 217 8.0 16.3 7.0 2.0 1.9
Africa 28.4 217.3 1029 580 31.3 240.0 17.7 1.6 1.3
Côte d’Ivoire 31.2 172.8 60 377 68.0 4.6 58.0 5.3 4.0
Comoros 34.2 83.8 108 707 4.4 40.5 20.7 3.3 2.9
Gabon 37.2 90.2 1918 580 40.7 42.8 25.1 3.4 2.9
Comoros 36.1 214 145 292 15.8 69.3 8.1 1.1 1.4
Cameroon 40.2 181.6 444 576 3.2 171 5.4 0.8 0.6
Comoros 66.0 60.2 304 176 18.5 78.9 13.1 3.5 4.6
Niger 66.3 79.9 331 393 37.4 61.0 20.1 0.7 0.5
Comoros 66.7 82.6 244 918 3.5 46.6 14.1 0.8 0.8
Benin 67.4 82.4 17 728 5.3 21.7 36.4 3.0 2.2
Comoros 69.4 46.0 246 210 5.3 82.4 6.4 1.9 1.9
Thailand 71.5 91.1 63 1131 166 34.4 114.0 21.2 16.3
Côte d’Ivoire 76.1 91.0 288 660 7.8 56.0 1.4 1.3 1.8
Comoros 80.0 82.0 321 587 32.9 47.2 6.7 2.5 3.5
High IC50s are in bold
ND: not determined
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[20]. In the present study, a positive correlation was
shown between PND and DHA or AS responses with a
coefficient of correlation rho = 0.18 and 0.19, respec-
tively. To suggest common mechanisms of action or
resistance for two compounds, that could induce cross-
resistance, the coefficient of determination must be
high, such as the one for AS and DHA (rho = 0.84 and
r2 = 0.68) corresponding to 68% of the variation in the
response to DHA is explained by variation in the
response to AS. A coefficient of determination of 0.027
or 0.038 means that only 2.7% and 3.8% of the variation
in the response to PND is explained by variation in the
response to DHA and AS. These data suggest that there
is no cross-resistance between PND and artemisinin
derivatives. In addition, the combination of PND and
AS has undergone successful clinical evaluation in
Africa [10,30]. In the present study, a positive correla-
tion was shown between PND and CQ responses with a
coefficient of correlation rho = 0.16 and r2 = 0.017. This
means that only 1.7% of the variation in the response to
PND is explained by variation in the response to CQ.
These data are consistent with the efficacy of the combi-
nation of PND and AS for areas in which parasites are
resistant to CQ [10,30]. There have been conflicting
reports on the correlations between P. falciparum
responses to PND and CQ. Previous studies showed
weak (from 0.003 to 0.26) [20,23-25,27] to modest (0.40
and 0.46) [19,21] coefficients of determination for corre-
lations between PND and CQ. PND appeared to be
equally effective in vitro against 37 isolates from two
areas of Thailand with different CQ resistance levels
[31]. Similarly, Basco and Le Bras showed no correlation
between resistance to PND and CQ for 31 isolates from
Central and West Africa [32]. These results suggest that
no cross-resistance exists between PND and CQ. In
addition, an isolate collected in a patient who took part
in trekking along the Mekong from the south of Laos to
the north of Thailand showed high susceptibility to CQ
and MDAQ and very low susceptibility to PND (71.5
nM), PPQ (91.1 nM), QN (1,131 nM), MQ (166 nM),
LMF (114 nM) and to the artemisinin derivatives DHA
(21.2 nM) and AS (16.3 nM) [33]. This multi-resistant
isolate was suspected of being resistant to ACT. All of
the other significant positive correlations between PND
and QN, MDAQ or LMF are too low (rho < 0.37, r2 <
0.10) to suggest cross-resistance between PND and qui-
noline drugs. This absence of cross-resistance may be
explained by the absence of association between PND
and genes involved in quinoline resistance, such as pfcrt,
pfmdr1, pfmrp or pfnhe-1 [20].
The highest coefficient of correlation was observed
between PND and PPQ (rho = 0.47 and r2 = 0.23). This
means that 23% of the variation in the response to PND
is explained by variation in the response to PPQ. This
result is also too low to suggest cross-resistance between
the two drugs. This result was in accordance with pre-
vious data (r2 = 0.20) [27].
In vitro drug interaction between PPQ and artemisinin
derivatives was indifferent or antagonistic [34-37]. How-
ever, PPQ has been combined with DHA and it has
undergone successful clinical evaluation in Africa, Asia
and South America [9,38-40]. In addition, PPQ-DHA is
also effective to treat P. vivax malaria [41]. But unfortu-
nately clinical failures to PPQ have been reported in
areas of China where it has been deployed in monother-
apy for P. falciparum [42].
The IC50 values for PPQ ranged from 11.8 to 217.3
nM (geometric mean = 66.8 nM, CI95% 61.8-72.3).
These data are in accordance with previous studies on
P. falciparum strains [35,43] or isolates from Cameroon
(geometric mean = 39 nM) [44], Thai-Burmese border
(49 nM) [45] and Kenya (50 nM) [46], but superior to
geometric mean of isolates from Uganda (6.1 nM) [47],
Indonesia (21.8 nM) [48] or Papua New Guinea [49].
The isolate with the highest IC50 to PPQ (217.3 nM)
was also resistant to CQ (1029 nM) and MDAQ (240
nM).
Encouragingly, PPQ has not shown any correlation
with the other quinoline drugs, i.e. CQ, QN, MDAQ,
LMF or MQ. These results suggest that no cross-resis-
tance exists between PPQ and CQ and the other quino-
line anti-malarial drugs. These data are in accordance
with previous studies, which showed weak coefficients
of determination included between 0.015 and 0.14 for
correlation between PPQ and CQ [43,45-47]. No signifi-
cant correlation was identified between PPQ and DHA
or AS. These data are in accordance with previous
results [47]. PPQ has shown no cross-resistance with
any of the anti-malarial drug tested. The absence of
cross-resistance may be explained by the absence of
association between PPQ and genes involved in quino-
line resistance, such as pfcrt, pfmdr1, pfmrp or pfnhe-1
[43]. A copy number variation event on chromosome 5
could be associated with PPQ resistance [50]. Transgene
expression studies are underway with individual genes
in this segment to evaluate their contribution to PPQ
resistance.
DHA-PPQ is an inexpensive, safe and highly effective
treatment for uncomplicated falciparum and vivax
malaria [41,51,52]. DHA-PPQ seems to offer a better
post-treatment prophylactic effect following therapy
compared with artemether-LMF [6,53,54] or AS-amo-
diaquine [55]. The significant lower risk of recurrent
parasitaemia after treatment with DHA-PPQ is likely to
be explained by differences in pharmacokinetics of the
non-artemisinin partner drugs. PPQ, a bisquinoline, is
estimated to have elimination half-life of 17-33 days
[38,56,57] while LMF and MDAQ have an estimated
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elimination half-life of two to six days and one-10 days
[58], respectively.
The PND-AS combination (Pyramax®) is one of the
latest ACT combinations currently under development
by the not-for-profit organisation Medicines for Malaria
Venture (Geneva, Switzerland) and the pharmaceutical
company Shin Poong Pharmaceuticals (Seoul, Republic
of Korea) for the treatment of uncomplicated P. falci-
parum malaria and for the blood stages of P. vivax
malaria. Pyramax® has recently completed phase III
trials in humans. A five-day regimen of PND alone
(total dose = 1800 mg) produced a better cure rate than
AS, artemether or MQ used alone in the same condi-
tions in Thailand [21]. Efficacy of PND-AS was non-
inferior to that of artemether-LMF for treatment of
uncomplicated falciparum malaria in Africa and South-
east Asia [10].
Conclusions
In this study, the excellent in vitro anti-malarial activ-
ities of the ACT components PPQ and PND on P. falci-
parum were confirmed. The absence of cross-resistance
with quinolines and artemisinin derivatives confirmed
the relevant use of the combinations of PPQ and DHA
or PND and AS in areas where parasites are resistant to
conventional anti-malarial drugs.
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